Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surgery vs Chemoradiation for Oropharyngeal Cancer
NCT05144100Phase 3Not yet recruiting
- Sponsor
- Tata Memorial Centre
- Start
- Dec 2021
- Primary completion
- Jun 2029
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in oropharyngeal squamous cell carcinoma (OPSCC) (2 arms), sponsored by Tata Memorial Centre. Primary endpoints: Event Free Survival at 5 years and Overall Survival at 5 years. Planned start Dec 2021; status: not yet recruiting.
02
Conditions
oropharyngeal squamous cell carcinoma (OPSCC)
Beyond the preview
Go deeper on NCT05144100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05144100.